04/12/2020 – AB Science announces that confirmatory Phase 3 study AB12005 with masitinib in first line pancreatic cancer with pain met its primary objective to demonstrate increase in survival Download PDF Post navigationPreviousPrevious post:Signature of a 15.0 million financing deal with the European Investment BankNextNext post:Live webcast on Friday December 11, 2020 on masitinib’s results in pancreatic cancerRelated PostsBoursorama interview of Alain Moussy, CEO of AB Science23 December 2020Capital raise for a total amount of 15 million euros21 December 2020Results from phase 2B/3 study evaluating masitinib in Alzheimer’s disease18 December 2020Masitinib in Alzheimer’s Disease Webcast Presentation17 December 2020Results of the Extraordinary General Shareholders’ Meeting of December 16, 202017 December 2020Corrective press release regarding adverse events information from study AB0900417 December 2020
